Live and in market: available on the App Store and Google Play with strong user ratings and reviews.
Documented clinical outcomes at scale: a five-year (2021–2026) real-world evaluation of 500,000+ users across nearly every country found that engagement with the app was associated with statistically significant reductions in depression and anxiety, with average PHQ-9 (depression) scores falling roughly 3.7 points — moving the typical user from the “moderately severe” range toward “moderate.” The study also revealed a clear dose–response effect: the more of UpLife’s CBT-based “Journeys” a user completed, the greater their symptom improvement.
